Estrogens as mediators of obesity-induced inflammation

Estrogens: Biochemistry, Therapeutic Uses and Physiological Effects

Volumn , Issue , 2012, Pages 1-46

  Teixeira, Diana ^a   Pestana, Diogo ^a   Calhau, Conceição ^a   Monteiro, Rosário ^a  

^a University of Porto   (Portugal)

Author keywords

Adipose tissue; Estrogens; Inflammation; Obesity

Indexed keywords

EID: 84892917029     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (215)

1. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 2003; 73:209-12.
2. Gordon S. Do macrophage innate immune receptors enhance atherogenesis? Dev Cell 2003; 5:666-8.
3. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112:1796-808.
4. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112:1821-30.
5. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25:677-86.
6. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3:23-35.
7. Cancello R, Tordjman J, Poitou C, et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006; 55:1554-61.
8. Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007; 56:16-23.
9. Lumeng CN, DelProposto JB, Westcott DJ, Saltiel AR. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 2008; 57:3239-46.
10. Murdoch C, Muthana M, Lewis CE. Hypoxia regulates macrophage functions in inflammation. J Immunol 2005; 175:6257-63.
11. Bourlier V, Zakaroff-Girard A, Miranville A, et al. Remodeling phenotype of human subcutaneous adipose tissue macrophages. Circulation 2008; 117:806-15.
12. Ohmura K, Ishimori N, Ohmura Y, et al. Natural killer T cells are involved in adipose tissues inflammation and glucose intolerance in diet-induced obese mice. Arterioscler Thromb Vasc Biol 2010; 30:193-9.
13. Caspar-Bauguil S, Cousin B, Galinier A, et al. Adipose tissues as an ancestral immune organ: site-specific change in obesity. FEBS Lett 2005; 579:3487-92.
14. Sell H, Eckel J. Adipose tissue inflammation: novel insight into the role of macrophages and lymphocytes. Curr Opin Clin Nutr Metab Care 2010; 13:366-70.
15. Winer S, Paltser G, Chan Y, et al. Obesity predisposes to Th17 bias. Eur J Immunol 2009; 39:2629-35.
16. Feuerer M, Herrero L, Cipolletta D, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 2009; 15:930-9.
17. Duffaut C, Galitzky J, Lafontan M, Bouloumie A. Unexpected trafficking of immune cells within the adipose tissue during the onset of obesity. Biochem Biophys Res Commun 2009; 384:482-5.
18. Kintscher U, Hartge M, Hess K, et al. T-lymphocyte infiltration in visceral adipose tissue -A primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arteriosclerosis Thrombosis and Vascular Biology 2008; 28:1304-10.
19. Keophiphath M, Rouault C, Divoux A, Clement K, Lacasa D. CCL5 Promotes Macrophage Recruitment and Survival in Human Adipose Tissue. Arteriosclerosis Thrombosis and Vascular Biology 2010; 30:39-U113.
20. Duffaut C, Zakaroff-Girard A, Bourlier V, et al. Interplay between human adipocytes and T lymphocytes in obesity: CCL20 as an adipochemokine and T lymphocytes as lipogenic modulators. Arterioscler Thromb Vasc Biol 2009; 29:1608-14.
21. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005; 25:2062-8.
22. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. Journal of Clinical Investigation 2006; 116:3015-25.
23. Nguyen MT, Favelyukis S, Nguyen AK, et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. Journal of Biological Chemistry 2007; 282:35279-92.
24. Jernas M, Palming J, Sjoholm K, et al. Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expression. FASEB J 2006; 20:1540-2.
25. Stienstra R, Duval C, Keshtkar S, van der Laak J, Kersten S, Muller M. Peroxisome proliferator-activated receptor gamma activation promotes infiltration of alternatively activated macrophages into adipose tissue. Journal of Biological Chemistry 2008; 283:22620-7.
26. Lacasa D, Taleb S, Keophiphath M, Miranville A, Clement K. Macrophage-secreted factors impair human adipogenesis: involvement of proinflammatory state in preadipocytes. Endocrinology 2007; 148:868-77.
27. Lee JY, Hwang DH. The modulation of inflammatory gene expression by lipids: mediation through Toll-like receptors. Mol Cells 2006; 21:174-85.
28. Straub RH. The complex role of estrogens in inflammation. Endocrine Reviews 2007; 28:521-74.
29. Green S, Kumar V, Krust A, Walter P, Chambon P. Structural and functional domains of the estrogen receptor. Cold Spring Harb Symp Quant Biol 1986; 51 Pt 2:751-8.
30. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996; 93:5925-30.
31. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138:863-70.
32. Roy JR, Chakraborty S, Chakraborty TR. Estrogen-like endocrine disrupting chemicals affecting puberty in humans--a review. Med Sci Monit 2009; 15:RA137-45.
33. Faulds MH, Zhao C, Dahlman-Wright K, Gustafsson JA. The diversity of sex steroid action: regulation of metabolism by estrogen signaling. Journal of Endocrinology 2012; 212:3-12.
34. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen receptor beta: an overview and update. Nucl Recept Signal 2008; 6:e003.
35. Nilsson S, Makela S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev 2001; 81:1535-65.
36. Metivier R, Reid G, Gannon F. Transcription in four dimensions: nuclear receptor-directed initiation of gene expression. EMBO Rep 2006; 7:161-7.
37. Gruber CJ, Gruber DM, Gruber IM, Wieser F, Huber JC. Anatomy of the estrogen response element. Trends Endocrinol Metab 2004; 15:73-8.
38. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev 2001; 81:1269-304.
39. Foryst-Ludwig A, Kintscher U. Metabolic impact of estrogen signalling through ERalpha and ERbeta. J Steroid Biochem Mol Biol 2010; 122:74-81.
40. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci U S A 1993; 90:11162-6.
41. Fisher CR, Graves KH, Parlow AF, Simpson ER. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci U S A 1998; 95:6965-70.
42. Krege JH, Hodgin JB, Couse JF, et al. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci U S A 1998; 95:15677-82.
43. Couse JF, Korach KS. Reproductive phenotypes in the estrogen receptor-alpha knockout mouse. Ann Endocrinol (Paris) 1999; 60:143-8.
44. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331:1056-61.
45. Grumbach MM, Auchus RJ. Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab 1999; 84:4677-94.
46. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005; 307:1625-30.
47. Filardo E, Quinn J, Pang Y, et al. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 2007; 148:3236-45.
48. Carmeci C, Thompson DA, Ring HZ, Francke U, Weigel RJ. Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 1997; 45:607-17.
49. Filardo EJ, Quinn JA, Bland KI, Frackelton AR, Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 2000; 14:1649-60.
50. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. Journal of Clinical Investigation 1999; 103:401-6.
51. Levin ER. Cellular Functions of the Plasma Membrane Estrogen Receptor. Trends Endocrinol Metab 1999; 10:374-7.
52. Norfleet AM, Thomas ML, Gametchu B, Watson CS. Estrogen receptor-alpha detected on the plasma membrane of aldehyde-fixed GH3/B6/F10 rat pituitary tumor cells by enzyme-linked immuno-cytochemistry. Endocrinology 1999; 140:3805-14.
53. Aronica SM, Kraus WL, Katzenellenbogen BS. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci U S A 1994; 91:8517-21.
54. Doolan CM, Harvey BJ. A Galphas protein-coupled membrane receptor, distinct from the classical oestrogen receptor, transduces rapid effects of oestradiol on [Ca2+]i in female rat distal colon. Mol Cell Endocrinol 2003; 199:87-103.
55. Carlezon WA, Jr., Duman RS, Nestler EJ. The many faces of CREB. Trends Neurosci 2005; 28:436-45.
56. Anwar A, McTernan PG, Anderson LA, et al. Site-specific regulation of oestrogen receptor-alpha and -beta by oestradiol in human adipose tissue. Diabetes Obesity & Metabolism 2001; 3:338-49.
57. Dos Santos EG, Dieudonne MN, Pecquery R, Le Moal V, Giudicelli Y, Lacasa D. Rapid nongenomic E2 effects on p42/p44 MAPK, activator protein-1, and cAMP response element binding protein in rat white adipocytes. Endocrinology 2002; 143:930-40.
58. Dieudonne MN, Leneveu MC, Giudicelli Y, Pecquery R. Evidence for functional estrogen receptors alpha and beta in human adipose cells: regional specificities and regulation by estrogens. Am J Physiol Cell Physiol 2004; 286:C655-61.
59. Cooke PS, Heine PA, Taylor JA, Lubahn DB. The role of estrogen and estrogen receptor-alpha in male adipose tissue. Molecular and Cellular Endocrinology 2001; 178:147-54.
60. Giguere V. Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocrine Reviews 2008; 29:677-96.
61. Fu M, Sun T, Bookout AL, et al. A Nuclear Receptor Atlas: 3T3-L1 adipogenesis. Mol Endocrinol 2005; 19:2437-50.
62. Barish GD, Downes M, Alaynick WA, et al. A Nuclear Receptor Atlas: macrophage activation. Mol Endocrinol 2005; 19:2466-77.
63. Frasor J, Barnett DH, Danes JM, Hess R, Parlow AF, Katzenellenbogen BS. Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the uterus. Endocrinology 2003; 144:3159-66.
64. Meseguer A, Puche C, Cabero A. Sex steroid biosynthesis in white adipose tissue. Hormone and Metabolic Research 2002; 34:731-6.
65. Belanger C, Luu-The V, Dupont P, Tchernof A. Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity. Hormone and Metabolic Research 2002; 34:737-45.
66. Jones MEE, McInnes KJ, Boon WC, Simpson ER. Estrogen and adiposity -Utilizing models of aromatase deficiency to explore the relationship. Journal of Steroid Biochemistry and Molecular Biology 2007; 106:3-7.
67. Jones MEE, Boon WC, Proietto J, Simpson ER. Of mice and men: the evolving phenotype of aromatase deficiency. Trends in Endocrinology and Metabolism 2006; 17:53-62.
68. Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. New England Journal of Medicine 1997; 337:91-5.
69. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640-5.
70. Sato K, Matsuki N, Ohno Y, Nakazawa K. Estrogens inhibit l-glutamate uptake activity of astrocytes via membrane estrogen receptor alpha. J Neurochem 2003; 86:1498-505.
71. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proceedings of the National Academy of Sciences of the United States of America 2000; 97:12729-34.
72. Danilovich N, Babu PS, Xing W, Gerdes M, Krishnamurthy H, Sairam MR. Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating hormone receptor knockout (FORKO) female mice. Endocrinology 2000; 141:4295-308.
73. Naaz A, Zakroczymski M, Heine P, et al. Effect of ovariectomy on adipose tissue of mice in the absence of estrogen receptor alpha (ERalpha): a potential role for estrogen receptor beta (ERbeta). Hormone and Metabolic Research 2002; 34:758-63.
74. Foryst-Ludwig A, Clemenz M, Hohmann S, et al. Metabolic Actions of Estrogen Receptor Beta (ER beta) are Mediated by a Negative Cross-Talk with PPAR gamma. Plos Genetics 2008; 4.
75. Nilsson S, Gustafsson JA. Estrogen receptors: therapies targeted to receptor subtypes. Clin Pharmacol Ther; 89:44-55.
76. Haas E, Bhattacharya I, Brailoiu E, et al. Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res 2009; 104:288-91.
77. Wang C, Dehghani B, Magrisso IJ, et al. GPR30 contributes to estrogen-induced thymic atrophy. Mol Endocrinol 2008; 22:636-48.
78. Hugo ER, Brandebourg TD, Woo JG, Loftus J, Alexander JW, Ben-Jonathan N. Bisphenol A at environmentally relevant doses inhibits adiponectin release from human adipose tissue explants and adipocytes. Environ Health Perspect 2008; 116:1642-7.
79. Murase Y, Kobayashi J, Nohara A, et al. Raloxifene promotes adipocyte differentiation of 3T3-L1 cells. Eur J Pharmacol 2006; 538:1-4.
80. Martensson UEA, Salehi SA, Windahl S, et al. Deletion of the G Protein-Coupled Receptor 30 Impairs Glucose Tolerance, Reduces Bone Growth, Increases Blood Pressure, and Eliminates Estradiol-Stimulated Insulin Release in Female Mice. Endocrinology 2009; 150:687-98.
81. Stubbins RE, Holcomb VB, Hong J, Nunez NP. Estrogen modulates abdominal adiposity and protects female mice from obesity and impaired glucose tolerance. Eur J Nutr 2011.
82. Riant E, Waget A, Cogo H, Arnal JF, Burcelin R, Gourdy P. Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. Endocrinology 2009; 150:2109-17.
83. Sudhir K, Chou TM, Chatterjee K, et al. Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 1997; 96:3774-7.
84. Schuit SC, Oei HH, Witteman JC, et al. Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA 2004; 291:2969-77.
85. Yoshihara R, Utsunomiya K, Gojo A, et al. Association of polymorphism of estrogen receptor-alpha gene with circulating levels of adiponectin in postmenopausal women with type 2 diabetes. J Atheroscler Thromb 2009; 16:250-5.
86. Lamon-Fava S, Asztalos BF, Howard TD, et al. Association of polymorphisms in genes involved in lipoprotein metabolism with plasma concentrations of remnant lipoproteins and HDL subpopulations before and after hormone therapy in postmenopausal women. Clin Endocrinol (Oxf); 72:169-75.
87. Eastwood H, Brown KM, Markovic D, Pieri LF. Variation in the ESR1 and ESR2 genes and genetic susceptibility to anorexia nervosa. Mol Psychiatry 2002; 7:86-9.
88. Nilsson S, Koehler KF, Gustafsson JA. Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov 2011; 10:778-92.
89. Mansur Ade P, Nogueira CC, Strunz CM, Aldrighi JM, Ramires JA. Genetic polymorphisms of estrogen receptors in patients with premature coronary artery disease. Arch Med Res 2005; 36:511-7.
90. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clinical Research in Cardiology 2006; 95:136-47.
91. Stork S, van der Schouw YT, Grobbee DE, Bots ML. Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. Trends in Endocrinology and Metabolism 2004; 15:66-72.
92. Lobo RA. Inflammation, coronary artery disease, and hormones. Menopause 2008; 15:1036-8.
93. Cignarella A, Kratz M, Bolego C. Emerging role of estrogen in the control of cardiometabolic disease. Trends Pharmacol Sci; 31:183-9.
94. Salama SA, Kamel MW, Diaz-Arrastia CR, et al. Effect of tumor necrosis factor-alpha on estrogen metabolism and endometrial cells: potential physiological and pathological relevance. J Clin Endocrinol Metab 2009; 94:285-93.
95. Roncari DA. Metabolism of estrogens in rat adipose tissue. Endocrinology 1967; 80:1160-3.
96. Anderson LA, McTernan PG, Barnett AH, Kumar S. The effects of androgens and estrogens on preadipocyte proliferation in human adipose tissue: Influence of gender and site. Journal of Clinical Endocrinology & Metabolism 2001; 86:5045-51.
97. Heine PA, Lubahn DB, Keisler DH, Hufford M, Cooke PS. Role of estrogen receptor alpha (ER alpha) in white adipose tissue (WAT) deposition in mice. Biology of Reproduction 2000; 62:306-7.
98. Jones ME, Thorburn AW, Britt KL, et al. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc Natl Acad Sci U S A 2000; 97:12735-40.
99. Bouchard C, Despres JP, Mauriege P. Genetic and nongenetic determinants of regional fat distribution. Endocrine Reviews 1993; 14:72-93.
100. Meinhardt UJ, Ho KK. Modulation of growth hormone action by sex steroids. Clin Endocrinol (Oxf) 2006; 65:413-22.
101. Horlick MB, Rosenbaum M, Nicolson M, et al. Effect of puberty on the relationship between circulating leptin and body composition. J Clin Endocrinol Metab 2000; 85:2509-18.
102. Nindl BC, Scoville CR, Sheehan KM, Leone CD, Mello RP. Gender differences in regional body composition and somatotrophic influences of IGF-I and leptin. J Appl Physiol 2002; 92:1611-8.
103. Sieminska L, Wojciechowska C, Niedziolka D, et al. Effect of postmenopause and hormone replacement therapy on serum adiponectin levels. Metabolism 2005; 54:1610-4.
104. Andersen KK, Frystyk J, Wolthers OD, Heuck C, Flyvbjerg A. Gender differences of oligomers and total adiponectin during puberty: A cross-sectional study of 859 Danish school children. Journal of Clinical Endocrinology & Metabolism 2007; 92:1857-62.
105. Asai K, Hiki N, Mimura Y, Ogawa T, Unou K, Kaminishi M. Gender differences in cytokine secretion by human peripheral blood mononuclear cells: role of estrogen in modulating LPS-induced cytokine secretion in an ex vivo septic model. Shock 2001; 16:340-3.
106. Garaulet M, Hernandez-Morante JJ, Tebar FJ, Zamora S. Anthropometric indexes for visceral fat estimation in overweight/obese women attending to age and menopausal status. J Physiol Biochem 2006; 62:245-52.
107. Haffner SM, Katz MS, Dunn JF. Increased upper body and overall adiposity is associated with decreased sex hormone binding globulin in postmenopausal women. Int J Obes 1991; 15:471-8.
108. Hautanen A. Synthesis and regulation of sex hormone-binding globulin in obesity. Int J Obes Relat Metab Disord 2000; 24 Suppl 2:S64-70.
109. De Pergola G, Zamboni M, Sciaraffia M, et al. Body fat accumulation is possibly responsible for lower dehydroepiandrosterone circulating levels in premenopausal obese women. Int J Obes Relat Metab Disord 1996; 20:1105-10.
110. Hernandez-Morante JJ, Perez-de-Heredia F, Lujan JA, Zamora S, Garaulet M. Role of DHEA-S on body fat distribution: gender-and depot-specific stimulation of adipose tissue lipolysis. Steroids 2008; 73:209-15.
111. Kant AK, Graubard BI. Secular trends in patterns of self-reported food consumption of adult Americans: NHANES 1971-1975 to NHANES 1999-2002. Am J Clin Nutr 2006; 84:1215-23.
112. Davidsen L, Vistisen B, Astrup A. Impact of the menstrual cycle on determinants of energy balance: a putative role in weight loss attempts. Int J Obes (Lond) 2007; 31:1777-85.
113. Asarian L, Geary N. Modulation of appetite by gonadal steroid hormones. Philos Trans R Soc Lond B Biol Sci 2006; 361:1251-63.
114. Geary N, Asarian L, Korach KS, Pfaff DW, Ogawa S. Deficits in E2-dependent control of feeding, weight gain, and cholecystokinin satiation in ER-alpha null mice. Endocrinology 2001; 142:4751-7.
115. Schneider JE. Energy balance and reproduction. Physiol Behav 2004; 81:289-317.
116. Shen L, Wang DQ, Lo CM, et al. Estradiol increases the anorectic effect of central apolipoprotein A-IV. Endocrinology; 151:3163-8.
117. Roepke TA. Oestrogen Modulates Hypothalamic Control of Energy Homeostasis Through Multiple Mechanisms. Journal of Neuro-endocrinology 2009; 21:141-50.
118. Musatov S, Chen W, Pfaff DW, et al. Silencing of estrogen receptor alpha in the ventromedial nucleus of hypothalamus leads to metabolic syndrome. Proc Natl Acad Sci U S A 2007; 104:2501-6.
119. Liang YQ, Akishita M, Kim S, et al. Estrogen receptor beta is involved in the anorectic action of estrogen. International Journal of Obesity 2002; 26:1103-9.
120. Chumlea WC, Knittle JL, Roche AF, Siervogel RM, Webb P. Size and number of adipocytes and measures of body fat in boys and girls 10 to 18 years of age. Am J Clin Nutr 1981; 34:1791-7.
121. Sjostrom L, Smith U, Krotkiewski M, Bjorntorp P. Cellularity in different regions of adipose tissue in young men and women. Metabolism-Clinical and Experimental 1972; 21:1143-53.
122. O'Sullivan AJ. Does oestrogen allow women to store fat more efficiently? A biological advantage for fertility and gestation. Obesity Reviews 2009; 10:168-77.
123. Hamosh M, Hamosh P. The effect of estrogen on the lipoprotein lipase activity of rat adipose tissue. Journal of Clinical Investigation 1975; 55:1132-5.
124. Palin SL, McTernan PG, Anderson LA, Sturdee DW, Barnett AH, Kumar S. 17Beta-estradiol and anti-estrogen ICI:compound 182,780 regulate expression of lipoprotein lipase and hormone-sensitive lipase in isolated subcutaneous abdominal adipocytes. Metabolism 2003; 52:383-8.
125. Ackerman GE, MacDonald PC, Gudelsky G, Mendelson CR, Simpson ER. Potentiation of epinephrine-induced lipolysis by catechol estrogens and their methoxy derivatives. Endocrinology 1981; 109:2084-8.
126. Misso ML, Murata Y, Boon WC, Jones MEE, Britt KL, Simpson ER. Cellular and molecular characterization of the adipose phenotype of the aromatase-deficient mouse. Endocrinology 2003; 144:1474-80.
127. Vegeto E, Bonincontro C, Pollio G, et al. Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. J Neurosci 2001; 21:1809-18.
128. Pozzi S, Benedusi V, Maggi A, Vegeto E. Estrogen action in neuro-protection and brain inflammation. Estrogens and Human Diseases 2006; 1089:302-23.
129. Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM. Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: Insights from basic science and clinical studies. Endocrine Reviews 2006; 27:575-605.
130. Stein B, Yang MX. Repression of the Interleukin-6 Promoter by Estrogen-Receptor Is Mediated by Nf-Kappa-B and C/Ebp-Beta. Mol Cell Biol 1995; 15:4971-9.
131. Ghisletti S, Meda C, Maggi A, Vegeto E. 17beta-estradiol inhibits inflammatory gene expression by controlling NF-kappaB intracellular localization. Mol Cell Biol 2005; 25:2957-68.
132. Murphy AJ, Guyre PM, Wira CR, Pioli PA. Estradiol regulates expression of estrogen receptor ERalpha46 in human macrophages. PLoS One 2009; 4:e5539.
133. Blasko E, Haskell CA, Leung S, et al. Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. J Neuroimmunol 2009; 214:67-77.
134. Deshpande R, Khalili H, Pergolizzi RG, Michael SD, Chang MD. Estradiol down-regulates LPS-induced cytokine production and NFkB activation in murine macrophages. Am J Reprod Immunol 1997; 38:46-54.
135. Frazier-Jessen MR, Kovacs EJ. Estrogen modulation of JE/monocyte chemoattractant protein-1 mRNA expression in murine macrophages. J Immunol 1995; 154:1838-45.
136. Dantas AP, Sandberg K. Estrogen regulation of tumor necrosis factor-alpha: a missing link between menopause and cardiovascular risk in women? Hypertension 2005; 46:21-2.
137. Arenas IA, Armstrong SJ, Xu Y, Davidge ST. Chronic tumor necrosis factor-alpha inhibition enhances NO modulation of vascular function in estrogen-deficient rats. Hypertension 2005; 46:76-81.
138. Geer EB, Shen W. Gender Differences in Insulin Resistance, Body Composition, and Energy Balance. Gender Medicine 2009; 6:60-75.
139. Szalowska E, Dijkstra M, Elferink MG, et al. Comparative analysis of the human hepatic and adipose tissue transcriptomes during LPS-induced inflammation leads to the identification of differential biological pathways and candidate biomarkers. BMC Med Genomics; 4:71.
140. Koh KK, Ahn JY, Kang MH, et al. Effects of hormone replacement therapy on plaque stability, inflammation, and fibrinolysis in hypertensive or overweight postmenopausal women. Am J Cardiol 2001; 88:1423-6, A8.
141. Rogers A, Eastell R. The effect of 17beta-estradiol on production of cytokines in cultures of peripheral blood. Bone 2001; 29:30-4.
142. Newbold RR, Padilla-Banks E, Jefferson WN, Heindel JJ. Effects of endocrine disruptors on obesity. Int J Androl 2008; 31:201-8.
143. Baillie-Hamilton PF. Chemical toxins: a hypothesis to explain the global obesity epidemic. J Altern Complement Med 2002; 8:185-92.
144. Bougneres P. Genetics of obesity and type 2 diabetes: tracking pathogenic traits during the predisease period. Diabetes 2002; 51 Suppl 3:S295-303.
145. Heindel JJ. Endocrine disruptors and the obesity epidemic. Toxicol Sci 2003; 76:247-9.
146. Grun F, Blumberg B. Environmental obesogens: organotins and endocrine disruption via nuclear receptor signaling. Endocrinology 2006; 147:S50-5.
147. Grun F, Watanabe H, Zamanian Z, et al. Endocrine-disrupting organotin compounds are potent inducers of adipogenesis in vertebrates. Mol Endocrinol 2006; 20:2141-55.
148. Grun F, Blumberg B. Perturbed nuclear receptor signaling by environmental obesogens as emerging factors in the obesity crisis. Rev Endocr Metab Disord 2007; 8:161-71.
149. Carson R. Silent Spring. 1962; Houghton Mifflin United States.
150. Kojima H, Sata F, Takeuchi S, Sueyoshi T, Nagai T. Comparative study of human and mouse pregnane X receptor agonistic activity in 200 pesticides using in vitro reporter gene assays. Toxicology; 280:77-87.
151. Gutendorf B, Westendorf J. Comparison of an array of in vitro assays for the assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens and xenoestrogens. Toxicology 2001; 166:79-89.
152. Witorsch RJ. Low-dose in utero effects of xenoestrogens in mice and their relevance to humans: an analytical review of the literature. Food Chem Toxicol 2002; 40:905-12.
153. Swedenborg E, Ruegg J, Makela S, Pongratz I. Endocrine disruptive chemicals: mechanisms of action and involvement in metabolic disorders. J Mol Endocrinol 2009; 43:1-10.
154. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389:753-8.
155. Blair RM, Fang H, Branham WS, et al. The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. Toxicol Sci 2000; 54:138-53.
156. Adeoya-Osiguwa SA, Markoulaki S, Pocock V, Milligan SR, Fraser LR. 17beta-Estradiol and environmental estrogens significantly affect mammalian sperm function. Human Reproduction 2003; 18:100-7.
157. Nadal A, Ropero AB, Laribi O, Maillet M, Fuentes E, Soria B. Nongenomic actions of estrogens and xenoestrogens by binding at a plasma membrane receptor unrelated to estrogen receptor alpha and estrogen receptor beta. Proc Natl Acad Sci U S A 2000; 97:11603-8.
158. Ruehlmann DO, Steinert JR, Valverde MA, Jacob R, Mann GE. Environmental estrogenic pollutants induce acute vascular relaxation by inhibiting L-type Ca2+ channels in smooth muscle cells. FASEB J 1998; 12:613-9.
159. Watson CS, Campbell CH, Gametchu B. Membrane oestrogen receptors on rat pituitary tumour cells: immuno-identification and responses to oestradiol and xenoestrogens. Exp Physiol 1999; 84:1013-22.
160. Wober J, Weisswange I, Vollmer G. Stimulation of alkaline phosphatase activity in Ishikawa cells induced by various phytoestrogens and synthetic estrogens. J Steroid Biochem Mol Biol 2002; 83:227-33.
161. Watson CS, Pappas TC, Gametchu B. The other estrogen receptor in the plasma membrane: implications for the actions of environmental estrogens. Environ Health Perspect 1995; 103 Suppl 7:41-50.
162. Bulayeva NN, Watson CS. Xenoestrogen-induced ERK-1 and ERK-2 activation via multiple membrane-initiated signaling pathways. Environ Health Perspect 2004; 112:1481-7.
163. Bulayeva NN, Gametchu B, Watson CS. Quantitative measurement of estrogen-induced ERK 1 and 2 activation via multiple membrane-initiated signaling pathways. Steroids 2004; 69:181-92.
164. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005; 146:624-32.
165. Quesada I, Fuentes E, Viso-Leon MC, Soria B, Ripoll C, Nadal A. Low doses of the endocrine disruptor bisphenol-A and the native hormone 17beta-estradiol rapidly activate transcription factor CREB. FASEB J 2002; 16:1671-3.
166. Canesi L, Lorusso LC, Ciacci C, Betti M, Zampini M, Gallo G. Environmental estrogens can affect the function of mussel hemocytes through rapid modulation of kinase pathways. Gen Comp Endocrinol 2004; 138:58-69.
167. Elobeid MA, Allison DB. Putative environmental-endocrine disruptors and obesity: a review. Curr Opin Endocrinol Diabetes Obes 2008; 15:403-8.
168. Oseni T, Patel R, Pyle J, Jordan VC. Selective estrogen receptor modulators and phytoestrogens. Planta Med 2008; 74:1656-65.
169. Newbold RR. Impact of environmental endocrine disrupting chemicals on the development of obesity. Hormones (Athens) 2010; 9:206-17.
170. Blake C, Fabick KM, Setchell KD, Lund TD, Lephart ED. Neuromodulation by soy diets or equol: anti-depressive & anti-obesity-like influences, age-& hormone-dependent effects. BMC Neurosci; 12:28.
171. Penza M, Montani C, Romani A, et al. Genistein affects adipose tissue deposition in a dose-dependent and gender-specific manner. Endo-crinology 2006; 147:5740-51.
172. Park HJ, Della-Fera MA, Hausman DB, Rayalam S, Ambati S, Baile CA. Genistein inhibits differentiation of primary human adipocytes. J Nutr Biochem 2009; 20:140-8.
173. Heim M, Frank O, Kampmann G, et al. The phytoestrogen genistein enhances osteogenesis and represses adipogenic differentiation of human primary bone marrow stromal cells. Endocrinology 2004; 145:848-59.
174. Szkudelska K, Nogowski L, Szkudelski T. Genistein affects lipogenesis and lipolysis in isolated rat adipocytes. J Steroid Biochem Mol Biol 2000; 75:265-71.
175. Harmon AW, Harp JB. Differential effects of flavonoids on 3T3-L1 adipogenesis and lipolysis. Am J Physiol Cell Physiol 2001; 280:C807-13.
176. Rogers NH, Perfield JW, 2nd, Strissel KJ, Obin MS, Greenberg AS. Reduced energy expenditure and increased inflammation are early events in the development of ovariectomy-induced obesity. Endocrinology 2009; 150:2161-8.
177. Wade GN, Gray JM, Bartness TJ. Gonadal Influences on Adiposity. International Journal of Obesity 1985; 9:83-92.
178. Lephart ED, Porter JP, Lund TD, et al. Dietary isoflavones alter regulatory behaviors, metabolic hormones and neuroendocrine function in Long-Evans male rats. Nutr Metab (Lond) 2004; 1:16.
179. Kim HK, Nelson-Dooley C, Della-Fera MA, et al. Genistein decreases food intake, body weight, and fat pad weight and causes adipose tissue apoptosis in ovariectomized female mice. J Nutr 2006; 136:409-14.
180. Naaz A, Yellayi S, Zakroczymski MA, et al. The soy isoflavone genistein decreases adipose deposition in mice. Endocrinology 2003; 144:3315-20.
181. Limer JL, Speirs V. Phyto-oestrogens and breast cancer chemopre-vention. Breast Cancer Res 2004; 6:119-27.
182. Dang ZC, Papapoulos S, Lowik C. Phytoestrogens enhance osteogenesis and concurrently inhibit adipogenesis. Journal of Nutrition 2002; 132:617s-s.
183. Thomas P, Dong J. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J Steroid Biochem Mol Biol 2006; 102:175-9.
184. Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. Journal of Endocrinology 2010; 204:105-14.
185. Wittassek M, Wiesmuller GA, Koch HM, et al. Internal phthalate exposure over the last two decades -A retrospective human bio-monitoring study. International Journal of Hygiene and Environmental Health 2007; 210:319-33.
186. Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Ekong J, Needham LL. Urinary concentrations of bisphenol A and 4-nonylphenol in a human reference population. Environmental Health Perspectives 2005; 113:391-5.
187. Pelletier C, Doucet E, Imbeault P, Tremblay A. Associations between weight loss-induced changes in plasma organochlorine concentrations, serum T-3 concentration, and resting metabolic rate. Toxicological Sciences 2002; 67:46-51.
188. Chevrier J, Dewailly E, Ayotte P, Mauriege P, Despres JP, Tremblay A. Body weight loss increases plasma and adipose tissue concentrations of potentially toxic pollutants in obese individuals. International Journal of Obesity 2000; 24:1272-8.
189. Goncharov A, Haase RF, Santiago-Rivera A, et al. High serum PCBs are associated with elevation of serum lipids and cardiovascular disease in a Native American population. Environmental Research 2008; 106:226-39.
190. Pelletier C, Despres JP, Tremblay A. Plasma organochlorine concen-trations in endurance athletes and obese individuals. Medicine and Science in Sports and Exercise 2002; 34:1971-5.
191. Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y, Taketani Y. Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocrine Journal 2004; 51:165-9.
192. Lee DH, Lee IK, Song K, et al. A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Examination Survey 1999-2002. Diabetes Care 2006; 29:1638-44.
193. Lee DH, Lee IK, Porta M, Steffes M, Jacobs DR, Jr. Relationship between serum concentrations of persistent organic pollutants and the prevalence of metabolic syndrome among non-diabetic adults: results from the National Health and Nutrition Examination Survey 1999-2002. Diabetologia 2007; 50:1841-51.
194. Lee MJ, Lin H, Liu CW, et al. Octylphenol stimulates resistin gene expression in 3T3-L1 adipocytes via the estrogen receptor and extracellular signal-regulated kinase pathways. Am J Physiol Cell Physiol 2008; 294:C1542-51.
195. Vandenberg LN, Hauser R, Marcus M, Olea N, Welshons WV. Human exposure to bisphenol A (BPA). Reproductive Toxicology 2007; 24:139-77.
196. Shin BS, Kim CH, Jun YS, et al. Physiologically based pharma-cokinetics of bisphenol A. J Toxicol Environ Health A 2004; 67:1971-85.
197. Nunez AA, Kannan K, Giesy JP, Fang J, Clemens LG. Effects of bisphenol A on energy balance and accumulation in brown adipose tissue in rats. Chemosphere 2001; 42:917-22.
198. Seidlova-Wuttke D, Jarry H, Christoffel J, Rimoldi G, Wuttke W. Effects of bisphenol-A (BPA), dibutylphtalate (DBP), benzophenone-2 (BP2), procymidone (Proc), and linurone (Lin) on fat tissue, a variety of hormones and metabolic parameters: A 3 months comparison with effects of estradiol (E2) in ovariectomized (ovx) rats. Toxicology 2005; 213:13-24.
199. Masuno H, Kidani T, Sekiya K, et al. Bisphenol A in combination with insulin can accelerate the conversion of 3T3-L1 fibroblasts to adipocytes. J Lipid Res 2002; 43:676-84.
200. Sakurai K, Kawazuma M, Adachi T, et al. Bisphenol A affects glucose transport in mouse 3T3-F442A adipocytes. Br J Pharmacol 2004; 141:209-14.
201. Gesta S, Tseng YH, Kahn CR. Developmental origin of fat: tracking obesity to its source. Cell 2007; 131:242-56.
202. Newbold RR, Padilla-Banks E, Snyder RJ, Phillips TM, Jefferson WN. Developmental exposure to endocrine disruptors and the obesity epidemic. Reprod Toxicol 2007; 23:290-6.
203. Zimmerman SA, Clevenger WR, Brimhall BB, Bradshaw WS. Diethylstilbestrol-induced perinatal lethality in the rat. II. Perturbation of parturition. Biology of Reproduction 1991; 44:583-9.
204. Clevenger WR, Cornwall GA, Carter MW, Bradshaw WS. Diethylstilbestrol-induced perinatal lethality in the rat. I. Relationship to reduced maternal weight gain. Biology of Reproduction 1991; 44:575-82.
205. Ema M, Miyawaki E. Effects on development of the reproductive system in male offspring of rats given butyl benzyl phthalate during late pregnancy. Reprod Toxicol 2002; 16:71-6.
206. Rubin BS, Murray MK, Damassa DA, King JC, Soto AM. Perinatal exposure to low doses of bisphenol A affects body weight, patterns of estrous cyclicity, and plasma LH levels. Environ Health Perspect 2001; 109:675-80.
207. Givens ML, Small CM, Terrell ML, et al. Maternal exposure to poly-brominated and polychlorinated biphenyls: Infant birth weight and gestational age. Chemosphere 2007; 69:1295-304.
208. Fein GG, Jacobson JL, Jacobson SW, Schwartz PM, Dowler JK. Prenatal Exposure to Polychlorinated-Biphenyls -Effects on Birth Size and Gestational-Age. Journal of Pediatrics 1984; 105:315-20.
209. Baker DJ, Fuhrman J, Renter F. Perspectives on organizational growth. Ment Retard 2002; 40:477-80.
210. Hochberg Z, Feil R, Constancia M, et al. Child health, developmental plasticity, and epigenetic programming. Endocrine Reviews 2002; 32:159-224.
211. Bromer JG, Wu J, Zhou Y, Taylor HS. Hypermethylation of homeobox A10 by in utero diethylstilbestrol exposure: an epigenetic mechanism for altered developmental programming. Endocrinology 2009; 150:3376-82.
212. Newbold RR. Lessons learned from perinatal exposure to diethylstil-bestrol. Toxicol Appl Pharmacol 2004; 199:142-50.
213. Dolinoy DC. Epigenetic gene regulation: early environmental exposures. Pharmacogenomics 2007; 8:5-10.
214. Avissar-Whiting M, Veiga KR, Uhl KM, et al. Bisphenol A exposure leads to specific microRNA alterations in placental cells. Reprod Toxicol; 29:401-6.
215. vom Saal FS, Akingbemi BT, Belcher SM, et al. Chapel Hill bisphenol A expert panel consensus statement: integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. Reprod Toxicol 2007; 24:131-8.